Pipeline

Through in-house discovery and strategic in-licensing with global best-in-class partners, we are accelerating the development and delivery of breakthrough medicines to patients around the world.

Brii Bio is building a pipeline of more than 10 novel therapeutic candidates that allows the Company to develop differentiated treatment options for patients based on two key methods:

The application of novel chemistry and extended-release formulation
The application of novel chemistry and extended-release formulation
Combination therapies to tackle the heterogeneity of complex diseases with a multi-prong approach
Combination therapies to tackle the heterogeneity of complex diseases with a multi-prong approach
Infectious Disease Programs
Indication
Program
Preclinical
IND
Phase 1
Phase 2
Phase 3
NDA/BLA
Brii Rights
Partners

Hepatitis B

More+
Preclinical:

Hepatitis B

Program:

BRII-179 (VBI-2601)/BRII-835 (VIR-2218) Combination

Preclinical
IND
Phase 1
Phase 2
Phase 3
NDA/BLA
Brii Rights:
Greater China*
Partners:
Preclinical:

Hepatitis B

Program:

BRII-179 (VBI-2601)/PEG-IFN-α Combination 

Preclinical
IND
Phase 1
Phase 2
Phase 3
NDA/BLA
Brii Rights:
Greater China*
Partners:
Preclinical:

Hepatitis B

Program:

BRII-877 (VIR-3434)(1)

Preclinical
IND
Phase 1
Phase 2
Phase 3
NDA/BLA
Brii Rights:
Greater China*
Partners:

HIV

More+
Preclinical:

HIV

Program:

 BRII-732

Preclinical
IND
Phase 1
Phase 2
Phase 3
NDA/BLA
Brii Rights:
Global
Partners:
Internally discovered
Preclinical:

HIV

Program:

 BRII-753

Preclinical
IND
Phase 1
Phase 2
Phase 3
NDA/BLA
Brii Rights:
Global
Partners:
Internally discovered

MDR/XDR Gram-negative Bacterial Infections

More+
Preclinical:

MDR/XDR Gram-negative Bacterial Infections

Program:

BRII-672 (ORAvance)(2)

Preclinical
IND
Phase 1
Phase 2
Phase 3
NDA/BLA
Brii Rights:
Greater China*
Partners:
Preclinical:

MDR/XDR Gram-negative Bacterial Infections

Program:

 BRII-693 (QPX9003)(2)

Preclinical
IND
Phase 1
Phase 2
Phase 3
NDA/BLA
Brii Rights:
Greater China*
Partners:
Preclinical:

MDR/XDR Gram-negative Bacterial Infections

Program:

BRII-636 (OMNIvance)(2)

Preclinical
IND
Phase 1
Phase 2
Phase 3
NDA/BLA
Brii Rights:
Greater China*
Partners:

NTM Lung Disease

More+
Preclinical:

NTM Lung Disease

Program:

BRII-658 (Epetraborole)(3)

Preclinical
IND
Phase 1
Phase 2
Phase 3
NDA/BLA
Brii Rights:
Greater China*
Partners:
Central Nervous System Disease Programs
Indication
Program
Preclinical
IND
Phase 1
Phase 2
Phase 3
NDA/BLA
Brii Rights
Partners

PPD

More+
Preclinical:

PPD

Program:

BRII-296 

Preclinical
IND
Phase 1
Phase 2
Phase 3
NDA/BLA
Brii Rights:
Global
Partners:
Internally discovered

Anxiety & Other Depressive Disorders

More+
Preclinical:

Anxiety & Other Depressive Disorders

Program:

BRII-296

Preclinical
IND
Phase 1
Phase 2
Phase 3
NDA/BLA
Brii Rights:
Global
Partners:
Internally discovered

Anxiety & Depressive Disorders

More+
Preclinical:

Anxiety & Depressive Disorders

Program:

BRII-297

Preclinical
IND
Phase 1
Phase 2
Phase 3
NDA/BLA
Brii Rights:
Global
Partners:
Internally discovered

*Greater China – Mainland China, Macau, Hong Kong and Taiwan

Source: Company information

(1) The Phase 2 clinical trials have been conducted by VIR

(2) To this date, the development and clinical trials have been conducted by Qpex

(3) To this date, the development and clinical trials have been conducted by AN2

Partners